Rankings
▼
Calendar
RIGL Q4 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$70M
+21.2% YoY
Gross Profit
$64M
91.5% margin
Operating Income
$23M
33.2% margin
Net Income
$268M
384.0% margin
EPS (Diluted)
$14.11
QoQ Revenue Growth
+0.5%
Cash Flow
Operating Cash Flow
$22M
Free Cash Flow
$22M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$514M
Total Liabilities
$122M
Stockholders' Equity
$391M
Cash & Equivalents
$41M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$70M
$58M
+21.2%
Gross Profit
$64M
$52M
+23.2%
Operating Income
$23M
$17M
+39.1%
Net Income
$268M
$14M
+1769.2%
Revenue Segments
Contract revenues from collaborations
$4M
100%
← FY 2025
All Quarters